[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cairo University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":594},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1095,0,25,[9,48,70,91,115,138,158,190,219,237,261,278,300,331,352,371,396,419,443,465,483,512,531,552,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652184","hyaluronic-acid-and-polynucleotides-with-connective-tissue-graft-and-coronally-advanced-flap-for-rt-ii-gingival-recession-100652184",false,"NCT07771244","Hyaluronic Acid and Polynucleotides With Connective Tissue Graft and Coronally Advanced Flap for RT II Gingival Recession","Assessment of Injectable Hyaluronic Acid Combined With Polynucleotides With Coronally Advanced Flap and Connective Tissue Graft in Treatment of RT II Gingival Recession Defects for Covering Gingival Recession","Inclusion Criteria:\n\n* Patients with RT II gingival recession.\n* Age range: 15-60 years.\n* Systemically healthy patients with no contraindications to surgery.\n* Patients who have not had previous periodontal surgery in the area of treatment.\n\nExclusion Criteria:\n\n* Periodontitis.\n* Active systemic disease affecting wound healing.\n* Pregnancy or breastfeeding.\n* Improperly aligned teeth or teeth with cervical restorations or crowns.\n* Non-carious cervical lesions","ALL","15 Years","60 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"NA","This case series will evaluate the effectiveness of injectable hyaluronic acid combined with polynucleotides as an adjunct to coronally advanced flap and connective tissue graft in patients with RT II gingival recession. Twelve patients will be included and followed for 6 months. Clinical outcomes will include percentage of root coverage, clinical attachment level gain, gingival thickness, probing depth, width of keratinized tissue, post-operative pain, and patient aesthetic satisfaction.",[28],"RT II Gingival Recession",[30,28,31,32,33,34],"Gingival Recession","Hyaluronic Acid","Polynucleotides","Coronally Advanced Flap","Connective Tissue Graft","NOT_YET_RECRUITING","2026-08-20",{"date":38,"type":39},"2026-08-21","ACTUAL",{"date":41,"type":22},"2026-09-01",{"date":43,"type":22},"2027-03-01",{"name":45,"class":46},"Cairo University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100638169","phase-2-bariatric-endoscopic-antral-myotomy-combined-with-fundal-gastric-mucosal-ablation-100638169","NCT07612527","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation","Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation for The Management of Obesity","Inclusion Criteria:\n\nBody mass index (BMI) of ≥ 30 kg\u002Fm2 up to 40 kg\u002Fm2. BMI of 27.0 to 29.9 kg\u002Fm2 will be included on the condition of the presence of at least 1 obesity-related comorbidity (Indications based according to the American and European societies for bariatric endoscopy guidelines)\n\nExclusion Criteria:\n\n* Subjects with any previous surgeries to the stomach\n* Any previous bariatric procedures\n* Any current medications for the management of obesity (must be stopped at least 3 months before recruitment)\n* Evidence of severe gastritis, gastric peptic ulcer, or gastric cancer\n* Coagulopathy\n* Pregnancy","18 Years",{"count":57,"type":22},10,[59],"PHASE2","The gastric fundus regulates appetite through orexigenic ghrelin-mediated and anorexigenic visceroceptive pathways. Accordingly, endoscopic gastric fundal mucosal ablation (GFMA) may benefit patients with obesity. Ablation not only affects these mechanisms, but similar to what happens after mucosal ablation for other indications (e.g. ESD for tumor removal), it is expected to cause shrinking of the fundus and reduce gastric volume.\n\nAnother potential target to achieve weight loss is gastric emptying. This is a critical step in digestion that has been found to be more rapid after prolonged exposure to a high-fat diet in both animal and human studies, with rapid emptying also being more common in young people with obesity in some studies. The bariatric endoscopic antral myotomy (BEAM) procedure has been shown to consistently delay gastric emptying without triggering symptoms of gastroparesis and to produce substantial weight loss.\n\nBoth GFMA and BEAM procedures have the advantages of being minimally invasive, performed completely endoscopic and less costly than surgical alternatives or other known endoscopic techniques like intragastric balloon or endoscopic sleeve gastroplasty.",[62,63],"Obesity & Overweight","Bariatric Endoscopy","RECRUITING",{"date":38,"type":39},{"date":36,"type":39},{"date":68,"type":22},"2027-12",{"name":45,"class":46},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":47},"100652889","electromyographic-effects-of-postural-correction-exercises-in-individuals-with-forward-head-posture-100652889","NCT07780396","Electromyographic Effects of Postural Correction Exercises in Individuals With Forward Head Posture","Electromyographic Changes in Masticatory and Cervical Muscles Following a Structured 10-week Postural Correction Exercise Program in Individuals With Asymptomatic Forward Head Posture: A Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\. Participants aged 18- 30 years. 2. Presence of forward head posture, defined as CVA of less than 50° with no symptoms of neck pain \\[18, 19\\]. 3. No treatment for TMD or cervical symptoms (e.g., medication, physical therapy, or intra-articular injection) within the previous 2 weeks.\n\nExclusion Criteria:\n\n* 1\\. Current or previous diagnosis of temporomandibular disorder (TMD), or the presence of TMD-related signs or symptoms (e.g., joint sounds, restricted mouth opening, or orofacial pain) during screening.\n\n  2\\. History of TMJ subluxation or dislocation that could interfere with mouth opening.\n\n  3\\. History of recent head or neck trauma. 4. Angle Class II or Class III malocclusion. 5. Postural abnormalities secondary to structural spinal deformities (e.g., scoliosis or kyphosis), rheumatic diseases, or other medical conditions affecting posture.\n\n  6\\. Missing posterior teeth, recent orthodontic treatment (within the previous 12 months), or dental restorations that altered occlusion.","30 Years",{"count":79,"type":22},60,[25],"This study investigates the effects of specific corrective exercises on EMG of masticatory and cervical muscles in individuals with forward head posture. The study's design will be a retrospective, double- blinded, randomized controlled trial. The participants will be randomly allocated to one of two groups: the exercise group and the control group. The training groups will perform a program consisting of two strengthening (deep cervical flexors and shoulder retractors) and two stretchings (cervical extensors and pectoral muscles) exercises. This exercise program will be repeated 4 times per week for 10 weeks, and each session lasted 30 minutes.\n\nThe pre\u002Fpost assessment of forward head posture will measure by using craniovertebral angle CVA. While the muscle activity EMG of the masseter, temporalis, splenius, upper trapezius, and SCM will measure pre and post-assessment using a biopic data acquisition system.",[83],"Forward Head Posture","2026-08-19",{"date":38,"type":39},{"date":87,"type":39},"2026-05-15",{"date":89,"type":22},"2026-10-30",{"name":45,"class":46},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":47},"100652742","effect-of-probiotic-on-cognitive-function-100652742","NCT07776145","Effect of Probiotic on Cognitive Function","Effect of Probiotic Supplementation on Cognitive Function and Gut-Brain Axis Modulation in Females With Mild Depression","Inclusion Criteria:\n\nFemales, aged 50-64 years\n\n* Presence of mild depressive symptoms, defined as a Beck Depression inventory II (BDI-II) total score between 14 and 19 (inclusive) at the screening visit.\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Moderate and severe depression (BDI-II score \\> 19) or active suicidal ideation (assessed by clinical interview).\n* Diagnosis of bipolar disorder, schizophrenia, or other major psychotic disorder.\n\nCurrent use of antidepressants, antipsychotics, mood stabilizers, or regular anxiolytics\n\n* Regular consumption of probiotics, prebiotics, or synbiotic supplements within the past 4 weeks.\n* Use of antibiotics or antifungals within the past 4weeks.\n* Known diagnosis of inflammatory bowel disease, celiac disease, or active irritable bowel syndrome with severe symptoms.\n* History of significant cardiovascular disease (e.g., atrial fibrillation, heart failure, recent MI), uncontrolled hypertension, or type 1 diabetes.\n* Current use of systemic hormone replacement therapy within the last 3 months.Research Template 6 Final Version: Jan 2024\n* Known allergy to any component of the probiotic or placebo.\n* Severe systemic illness (e.g., uncontrolled diabetes, malignancy, severe hepatic, renal disease or auto-immune diseases).\n* CRP more than 10","FEMALE","50 Years","64 Years",{"count":102,"type":22},88,[25],"The goal of this clinical trial is to learn if daily single-strain probiotic supplementation (Lactobacillus plantarum) works to improve cognitive function and depressive symptoms in Egyptian women aged 50-64 years with mild depression. It will also learn about its effects on systemic inflammation and autonomic nervous system function via the gut-brain axis\n\nThe main questions it aims to answer are:\n\nDoes a 12-week probiotic supplementation improve cognitive function (measured by MoCA-B) compared to a placebo? Does it reduce the severity of depressive symptoms (measured by BDI-II)? Does it reduce systemic inflammation (measured by hs-CRP levels in the blood)? Does it enhance autonomic nervous system function (measured by Heart Rate Variability - HRV via a smartphone app)? Researchers will compare the probiotic capsule (Lactobacillus plantarum, 10 billion CFU) to a placebo (a look-alike capsule containing starch) to see if the probiotic works better than placebo.\n\nParticipants will:\n\nTake one probiotic or placebo capsule orally every morning with breakfast for 12 weeks.\n\nVisit the Family Medicine outpatient clinic at baseline and at 12 weeks for cognitive and psychological tests, HRV measurements, and blood tests.\n\nReceive weekly follow-up messages on WhatsApp to monitor adherence and report any dietary changes or potential side effects.",[106,107],"Cognition Function","Mild Depression","2026-08-18",{"date":36,"type":39},{"date":111,"type":22},"2026-09",{"date":113,"type":22},"2027-10",{"name":45,"class":46},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":47},"100652646","transverse-perineal-support-with-starr-for-anterior-rectocele-with-excessive-perineal-descent-100652646","NCT07777146","Transverse Perineal Support With STARR for Anterior Rectocele With Excessive Perineal Descent","Effect of Adding Transverse Perineal Support to Stapled Transanal Rectal Resection for Anterior Rectocele With Excessive Perineal Descent: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients complaining of obstructed defecation syndrome with anterior rectocele ≥ 3 cm associated with excessive perineal descent with failure of conservative management.\n\nExclusion Criteria:\n\n* Patients with Slow-transit constipation\n* Patients with anterior rectocele of \\\u003C 3 cm\n* Patients with complete external rectal prolapse\n* Evidence of colorectal carcinoma or Inflammatory bowel disease ( IBD)\n* Inability for lifestyle change postoperatively\n* Patients with fecal incontinence\n* Previous surgeries for anterior rectocele",{"count":123,"type":22},64,[25],"This prospective randomized controlled trial will include adult patients with ODS, anterior rectocele ≥3 cm, and excessive perineal descent following failure of conservative treatment.\n\nPatients will be randomized 1:1 to STARR alone or STARR combined with transverse perineal support procedure using polypropylene mesh. The primary outcome will be Change in Altomare Obstructed Defecation Syndrome (ODS) score in both groups. Secondary outcomes will include operative time, postoperative pain, surgical complications, surgical site infection, and sexual function assessed using the PISQ-12. Patients will be followed up twice during the first postoperative week, weekly during the first month, and monthly thereafter.",[127,128],"Rectocele","Perineal Descent",[130,128,131],"rectocele","Transverse Perineal Support",{"date":36,"type":39},{"date":134,"type":22},"2026-09-02",{"date":136,"type":22},"2028-01",{"name":45,"class":46},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":98,"minAge":99,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":142,"conditions":148,"keywords":151,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":155,"leadSponsor":157,"locationsCount":47},"100651681","reverse-fly-exercise-on-supraspinatus-tendinitis-in-patients-receiving-aromatase-inhibitors-therapy-after-mastectomy-100651681","NCT07763080","Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy","Inclusion Criteria:\n\n* Age range between 50:70 years.\n* Female patients participate in the study.\n* All patients with unilateral mastectomy.\n* Patients who receiving aromatase inhibitors treatment.\n* All patients will enroll in this study with have their informed consent.\n\nExclusion Criteria:\n\n* Patients have Metastases\n* Patients with Lymphedema\n* Patients with Rheumatoid arthritis\n* Patients have Neurological deficits (stroke, Parkinsonism)\n* Patients with Psychological disorders","70 Years",{"count":146,"type":22},40,[25],[149,150],"Mastectomy","Aromatase Inhibitors Therapy",[149,152],"Aromatase inhibitors therapy",{"date":84,"type":39},{"date":108,"type":22},{"date":156,"type":22},"2027-07-11",{"name":45,"class":46},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":17,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":175,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":47},"100652708","effects-of-otago-exercise-versus-multisensory-integration-training-on-balance-and-gait-in-elderly-with-diabetes-100652708","NCT07776535","Effects Of Otago Exercise Versus Multisensory Integration Training On Balance And Gait In Elderly With Diabetes","Balance - DM","Inclusion Criteria:\n\n1. Ninety elderly Patients of both genders.\n2. Their age will range from 65 to 75th.\n3. They will be diagnosed with type 2 diabetes for 5 years or more.\n4. Patients with mild \\& moderate neuropathy will be included. (Based on the Toronto scale: -mild (6-8); moderate (9-11)\n5. Berg balance between (21 to \\\u003C50) patients with mild \\&moderate risk of fall .\n6. Time up \\& go dual task: patient takes longer than 10 sec.\n7. HBA1C for these patients was ≥ 6.5% .\n8. BMI will range from (18: 29,9 kg\u002Fm2).\n9. Able to walk independently, with or without assistive devices.\n\nExclusion Criteria:\n\n1. Any musculoskeletal disorder affecting the lower limb (fracture of the lower limb, tumors, any infection, ligament injuries, foot injuries).\n2. Any other neurological disorder influences gait such as (stroke, Parkinson's disease, cerebellar dysfunction, ataxia, vestibular disorders)\n3. Any other cardiovascular disease (arrhythmia, cardiac pacemakers).\n4. Unstable proliferative retinopathy and visual impairments without correction.\n5. Non-diabetic neuropathy (inflammatory, autoimmune disease, infections, tumors, vitamin B12 deficiency, hypothyroidism, alcoholism, injury or pressure on the nerve).\n6. The use of medications significantly impacting postural control (e.g., sedatives).\n7. Vestibular system and Cognitive disorders.\n8. Uncontrolled hypertension.\n9. Common peroneal nerve injury.\n10. Orthostatic hypotension.","65 Years","75 Years",{"count":168,"type":22},90,[25],"The goal of this clinical trial is to compare the effect of the Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus.\n\nThe main question it aims to answer is:\n\n• Is there a significant difference between the effect of Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus? Researchers will compare Otago exercise to Multisensory integration training to know which one has the greatest benefit on balance \\&gait in the elderly with type2 diabetes.\n\nParticipants will be divided into 3 groups; each group takes a certain training program for 8 weeks:\n\n* First group: Otago exercise group plus conventional treatment for neuropathy.\n* Second group: Multisensory integration training group plus conventional treatment for neuropathy.\n* Third group: control group takes only conventional treatment for neuropathy.",[172,173,174],"Balance","Gait","Diabetes Mellitus",[176,177,178,179,180,181,182],"otago exercise","multisensory integration","balance disorder","gait proplem","diabetes","elderly","older adults","2026-08-17",{"date":36,"type":39},{"date":186,"type":22},"2026-10",{"date":188,"type":22},"2027-11",{"name":45,"class":46},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":197,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":208,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":218,"locationsCount":4},"100652430","clinical-and-radiographic-success-of-calcium-hydroxide-iodoform-paste-versus-modified-triple-antibiotic-paste-for-necrotic-primary-molars-in-children-100652430","NCT07773805","Clinical and Radiographic Success of Calcium Hydroxide-Iodoform Paste Versus Modified Triple Antibiotic Paste for Necrotic Primary Molars in Children","Assessment of the Clinical and Radiographic Success of Calcium Hydroxide Iodoform Paste Versus Modified Triple Antibiotic Paste for the Treatment of Necrotic Primary Molars Using LSTR Technique: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Pediatric patients aged 4-7 years\n* Positive parental informed consent\n* Restorable necrotic mandibular second primary molars with peri-radicular\u002Ffurcal involvement and\u002For pathologic root resorption (external or internal one-third to two-thirds of the root)\n* Presence of chronic apical abscess or sinus tract or furcation radiolucency\n\nExclusion Criteria:\n\n* Medically compromised patient\n* Children with a known allergy to any of the components being utilized\n* Molars near exfoliation\n* Molars with severely resorbed roots more than two thirds, indicated for extraction\n* Molar with insufficient coronal structure disabling proper coronal seal\n* Presence of a periapical or interradicular radiolucent area which could compromise the permanent tooth bud","4 Years","7 Years",{"count":200,"type":22},50,[25],"This randomized clinical trial aims to compare the clinical and radiographic success of calcium hydroxide-iodoform paste and modified triple antibiotic paste when used for the treatment of necrotic primary molars in children using the lesion sterilization and tissue repair (LSTR) technique. The study will include children aged 4-7 years with restorable necrotic mandibular second primary molars. Participants will be randomly assigned to receive LSTR treatment with either calcium hydroxide-iodoform paste or modified triple antibiotic paste. Clinical and radiographic findings will be assessed during follow-up over 12 months to determine the success of each treatment. The study hypothesis is that there will be a difference in the clinical and radiographic success between the two treatment materials when used with the LSTR technique",[204,205,206,207],"Dental Pulp Necrosis","Periapical Diseases","Dental Caries","Primary Teeth",[209,204,210,211,212],"Lesion Sterilization and Tissue Repair","Calcium Hydroxide-Iodoform Paste","Modified Triple Antibiotic Paste","Necrotic Primary Teeth","2026-08-16",{"date":84,"type":39},{"date":216,"type":22},"2027-01",{"date":136,"type":22},{"name":45,"class":46},{"id":220,"slug":221,"hasResults":12,"nctId":222,"briefTitle":223,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":17,"minAge":225,"maxAge":144,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":47},"100652330","efficacy-of-ai-driven-and-traditional-physical-therapy-programs-in-patients-with-knee-osteoarthritis-100652330","NCT07774195","Efficacy of AI-Driven and Traditional Physical Therapy Programs in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Participants will be recruited through outpatient orthopedic clinics and community health centers affiliated with the study sites.\n* Their age will be ranged from 45-70 years.\n* Their body mass index (BMI) will be ranged from 24.9 to 30 kg \u002Fm2 .\n* With a clinical and radiographic diagnosis of knee osteoarthritis based on American College of Rheumatology criteria, with Kellgren-Lawrence grade II or III osteoarthritis, and who will able to ambulate\n* Independently walk without assistive devices.\n\nExclusion Criteria:\n\n* Prior knee replacement surgery, inflammatory arthritis (e.g., rheumatoid arthritis).\n* Recent intra-articular steroid injections within three months.\n* Neurologic impairments affecting lower limb function.\n* Inability to comprehend or use the mobile application due to cognitive or sensory impairments.","45 Years",{"count":146,"type":22},[25],"This study aims to compare the effectiveness of an artificial intelligence (AI)-guided physical therapy program with a traditional physical therapy program in patients with knee osteoarthritis.\n\nForty patients with knee osteoarthritis will be randomly assigned to one of two groups. The traditional physical therapy group will receive a conventional rehabilitation program including transcutaneous electrical nerve stimulation (TENS), strengthening, flexibility, and balance exercises. The AI-guided group will receive an individualized rehabilitation program generated using ChatGPT-4 based on standardized patient information and clinical assessment findings.\n\nBoth groups will receive education regarding lifestyle modification and joint protection strategies. The effects of the two rehabilitation approaches will be evaluated by measuring pain intensity, knee range of motion, knee-related functional ability, and functional mobility and fall risk before and after the intervention.\n\nThe study will determine whether an AI-guided physical therapy program can provide outcomes comparable or superior to those of traditional physical therapy in individuals with knee osteoarthritis.",[230],"Knee Osteoarthritis","2026-08-14",{"date":84,"type":39},{"date":38,"type":22},{"date":235,"type":22},"2026-11-30",{"name":45,"class":46},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":19,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":258,"leadSponsor":260,"locationsCount":47},"100652227","polynucleotide-hyaluronic-acid-gel-with-xenograft-for-alveolar-ridge-preservation-100652227","NCT07771257","Polynucleotide-Hyaluronic Acid Gel With Xenograft for Alveolar Ridge Preservation","Evaluation of the Efficacy of Polynucleotide-Hyaluronic Acid Gel With Xenograft Compared to Xenograft Alone in Alveolar Ridge Preservation: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients aged 18-60 years.\n* Patients free from systemic diseases affecting wound healing or bone regeneration or contraindicating oral surgery.\n* Non-smokers with good oral hygiene.\n* Patients requiring tooth extraction in non-infected sockets due to endodontic failure, non-restorable caries, or trauma, and who will receive implant treatment.\n* Class I extraction sockets with intact alveolar bone walls.\n* Presence of teeth adjacent to the extraction site.\n\nExclusion Criteria:\n\n* Use of drugs affecting wound healing.\n* Heavy smokers (\\>10 cigarettes\u002Fday) or history of substance abuse.\n* Pregnant or breastfeeding women.\n* Previous grafting or surgical intervention in the study area.\n* Uncontrolled and\u002For untreated periodontal disease (active periodontitis).\n* Mentally or physically handicapped patients.",{"count":245,"type":22},20,[25],"This randomized controlled clinical trial will evaluate the efficacy of polynucleotide-hyaluronic acid gel combined with xenograft and collagen membrane for alveolar ridge preservation following tooth extraction. Twenty participants will be randomly allocated into two parallel groups. The test group will receive xenograft mixed with polynucleotide-hyaluronic acid gel and covered with a collagen membrane, while the control group will receive xenograft with a collagen membrane alone. Clinical and CBCT assessments will be performed at baseline and during follow-up. After 6 months, ridge dimensional changes will be evaluated and core biopsies will be obtained at the time of implant placement for histological assessment.",[249],"Alveolar Ridge Preservation",[251,249,252,31,253,254],"Socket Preservation","Polynucleotide","Xenograft","Collagen Membrane","2026-08-13",{"date":108,"type":39},{"date":111,"type":22},{"date":259,"type":22},"2027-04",{"name":45,"class":46},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":98,"minAge":77,"maxAge":225,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":47},"100652200","effect-of-low-level-laser-therapy-on-women-with-obstructive-defecation-syndrome-100652200","NCT07771218","Effect of Low Level Laser Therapy on Women With Obstructive Defecation Syndrome","Effect of Low Level Laser Therapy on Women With Obstructive Defecation Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Woman diagnosed with ODS according to the Renzi ODS score (≥ 9).\n* They suffer from difficult defecation for at least three months.\n* Their ages will range from 30-45 years old.\n* Their body mass index (BMI) will range from 25-30 kg\u002Fm2.\n* Their parity number will be 2-3 times.\n\nExclusion Criteria:\n\n* Any abnormalities around cancer colon, interstitial cystitis, or endometriosis.\n* Enlarged rectal diameter and damaged mienteric plexus and abnormal motor function of rectum.\n* Psychological or mental health problems.\n* Pregnancy and lactation\n* A history of previous pelvic surgery.\n* A history of retinopathy.",{"count":146,"type":22},[25],"Obstructive defecation syndrome (ODS) is a condition in which a person has difficulty completely emptying the rectum during bowel movements. Women with ODS may experience excessive straining, a feeling of incomplete evacuation or blockage, abdominal discomfort, and the need to use manual assistance, laxatives, or enemas to facilitate defecation.\n\nThis randomized controlled trial will investigate the effect of adding low-level laser therapy (LLLT) to a conventional treatment program for women with ODS. Participants will be randomly assigned to one of two groups. The control group will receive nutritional modification and biofeedback training, while the study group will receive the same treatment in addition to low-level laser therapy applied to the lumbosacral region.\n\nThe study will evaluate whether adding low-level laser therapy can improve anorectal function, reduce the severity of ODS symptoms, and improve health-related quality of life compared with conventional treatment alone.",[272],"Obstructive Defecation Syndrome",{"date":108,"type":39},{"date":36,"type":22},{"date":276,"type":22},"2026-12-31",{"name":45,"class":46},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":225,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":4},"100652106","effect-of-prophylaxis-pastes-with-and-without-desensitizing-agents-prior-to-in-office-bleaching-100652106","NCT07770373","Effect of Prophylaxis Pastes With and Without Desensitizing Agents Prior to In-office Bleaching","Effect of Prophylaxis Pastes With and Without Desensitizing Agents Prior to In-office Bleaching on Color Change and Tooth Sensitivity: Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients who have discolored teeth, minimum of 20 natural teeth, good oral hygiene, do not have any systemic disease.\n\nExclusion Criteria:\n\n* Patients who have extensive prosthesis or restoration, tetracycline discoloration or fluorosis, endodontically treated teeth or gingival recession, smokers, periodontal disease, pregnant or lactating.",{"count":286,"type":22},38,[25],"To evaluate the effect of prophylaxis pastes with and without desensitizing agents prior to in-office bleaching on color change and tooth sensitivity.",[290],"Discolored Teeth",[292,293,294],"bleaching","desensitizing agents","discoloration",{"date":108,"type":39},{"date":297,"type":22},"2026-08",{"date":297,"type":22},{"name":45,"class":46},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":17,"minAge":309,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":313,"phases":4,"briefSummary":314,"conditions":315,"keywords":317,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":326,"completionDateStruct":328,"leadSponsor":330,"locationsCount":4},"100652065","fine-motor-performance-in-school-aged-children-100652065","NCT07767656","Fine Motor Performance in School-aged Children","Core Stability and Fine Motor Performance in Typically Developing School-Aged Children","HGS\u002FHLS","Inclusion Criteria:\n\nChildren will be included in the study according to the following criteria:\n\n* Typically developing children aged 8-12 years.\n* Both boys and girls.\n* Enrolled in primary school.\n* Able to understand and follow simple verbal instructions.\n* Able to read and write in English according to their educational level.\n* Regular school attendance.\n* Children with a typical level of physical activity for their age and not participating in competitive athletic training programs.\n* Written informed consent obtained from parents or legal guardians.\n\nExclusion Criteria:\n\n* History of neurological, developmental, or musculoskeletal disorders affecting posture, upper limb function, or handwriting.\n* Upper limb pain, deformity, fracture, or injury within the previous six months.\n* Uncorrected visual or hearing impairment.\n* Diagnosed developmental coordination disorder (DCD), autism spectrum disorder (ASD), attention-deficit\u002Fhyperactivity disorder (ADHD), intellectual disability, or specific learning disorder affecting handwriting.\n* Previous surgery involving the upper limb or spine",true,"8 Years","12 Years",{"count":312,"type":22},100,"OBSERVATIONAL","The goal of this observational cross-sectional study is to investigate the relationship between core stability, hand grip strength, and handwriting performance in typically developing school-aged children aged 8 to 12 years. The study aims to determine whether core stability is associated with upper extremity function and handwriting abilities during middle childhood.\n\nThe main questions the study aims to answer are:\n\n* Is there a relationship between core stability and hand grip strength in typically developing school-aged children?\n* Is there a relationship between core stability and handwriting performance in typically developing school-aged children?\n\nParticipants will undergo the following assessments:\n\n* Assessment of core stability using the McGill core endurance tests.\n* Measurement of hand grip strength using a hydraulic hand dynamometer.",[316],"Healthy Children",[318,319,320,321,322,323],"core stability","fine motor performance","hand grip strength","hand writing performance","typically developing children","school aged children","2026-08-11",{"date":183,"type":39},{"date":327,"type":22},"2026-09-20",{"date":329,"type":22},"2027-03-20",{"name":45,"class":46},{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":313,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":47},"100651349","evaluating-ai-for-diagnosing-and-treating-gummy-smiles-a-pilot-study-100651349","NCT07759843","Evaluating AI for Diagnosing and Treating Gummy Smiles: A Pilot Study","Assessment of the Diagnostic Accuracy of Artificial Intelligence in Gummy Smile Diagnosis & Treatment Planning: A Pilot Study","Inclusion Criteria:\n\n* Properly treated gummy smile cases either surgical through crown lengthening procedure \u002F Orthognathic Surgery or non-surgical through orthodontic treatment \u002FBotox injection.\n\nExclusion Criteria:\n\n* Improperly treated gummy smile cases",{"count":339,"type":22},210,"Some people have a \"gummy smile,\" where too much gum tissue shows when they smile. Doctors currently diagnose this by hand, using rulers and visual judgment. This study is testing whether a computer program using artificial intelligence (AI) can help identify and measure gummy smiles from photographs, as accurately as expert dentists do it manually.\n\nPatients seen at Cairo University's Periodontics and Orthodontics clinics will have photos of their smile taken. Researchers will use these photos to first \"teach\" the AI program how to recognize and measure a gummy smile. Then, the AI will be tested on a new set of patient photos, and its measurements will be compared to measurements made by expert dentists, to see how closely they match.\n\nThe goal is to find out whether this AI tool could one day help doctors diagnose gummy smiles more quickly and consistently, which may improve care for patients.",[342,343],"Gummy Smile","Artifical Intelligence","2026-08-10",{"date":346,"type":39},"2026-08-12",{"date":348,"type":39},"2024-12-01",{"date":350,"type":22},"2026-12-01",{"name":45,"class":46},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":98,"minAge":359,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":369,"leadSponsor":370,"locationsCount":47},"100651850","impact-of-tibial-nerve-stimulation-on-lumbopelvic-mechanics-and-sexual-function-in-females-with-sexual-dysfunctions-100651850","NCT07764445","Impact of Tibial Nerve Stimulation on Lumbopelvic Mechanics and Sexual Function in Females With Sexual Dysfunctions","Impact of Transcutaneous Tibial Nerve Stimulation on Lumbopelvic Mechanics and Sexual Function in Females With Sexual Dysfunctions and Low Back Pain: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Females are diagnosed with low back pain combined with female sexual dysfunction.\n* Their ages will be ranged from 25 to 35 years.\n* Their body mass index (BMI) will be ranged from 23-28 kg\u002Fm2.\n* Patients with a number of normal deliveries ≤ three times\n* They had regular menstruation.\n\nExclusion Criteria:\n\n* Prior history of disc prolapse and sacroiliac joints, symphysis pubic joint as well as lower limb problems.\n* Genital prolapse.\n* Leg length discrepancy.\n* Urinary tract infection.\n* Diastasis recti, diabetes, intrauterine device.\n* Surgery related to the spine, abdomen or pelvis as well as skin disease that interferes with the usage of TTNS.","25 Years","35 Years",{"count":146,"type":22},[25],"This study will be conducted to examine the effects of Transcutaneous Tibial Nerve Stimulation (TTNS) on lumbopelvic mechanics and sexual function in females with sexual dysfunctions and low back pain",[365],"Female Sexual Dysfunction (FSD)","2026-08-09",{"date":231,"type":39},{"date":297,"type":22},{"date":235,"type":22},{"name":45,"class":46},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":308,"sex":17,"minAge":77,"maxAge":19,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":395,"locationsCount":4},"100650709","evaluation-of-subgingival-1-metformin-gel-versus-005-zoledronate-gel-as-an-adjunct-to-minst-of-intrabony-defects-in-controlled-type-2-dm-100650709","NCT07753317","Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM","Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to Minimally Invasive Nonsurgical Treatment of Intrabony Defects in Controlled Type 2 Diabetic Patients With Periodontitis. A Placebo Randomized Controlled Trial.","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus, with HbA1c levels \\\u003C7.0% (controlled).\n* Diagnosis of chronic periodontitis (Stage III\u002FIV, Grade B\u002FC) with at least one intrabony defect of ≥3 mm depth, PPD ≥5 mm, and CAL ≥4 mm measured with a calibrated UNC-15 probe.\n* Angular bone loss of ≥3 mm measured on digital intraoral periapical radiographs and having three walled intrabony defects without involving furcation confirmed on cone beam computed tomography (CBCT).\n\nExclusion Criteria:\n\n1. Smokers.\n2. Pregnant or lactating women.\n3. Patients on systemic bisphosphonate therapy or other medications known to affect bone metabolism.\n4. Uncontrolled diabetes (HbA1c \\>8%) or other systemic diseases that could affect periodontal status.\n5. History of radiation therapy to the head and neck",{"count":379,"type":22},30,[25],"The present randomized placebo-controlled trial aims to evaluate and compare the clinical and radiographic efficacy of subgingivally delivered 0.05% zoledronate gel and 1% metformin gel as adjuncts to minimally invasive nonsurgical treatment of intrabony defects in patients with controlled type 2 diabetes mellitus and periodontitis.",[383],"Controlled Type 2 Diabetic Patients With Periodontitis",[385,386,387,388,389,390],"Metformin gel","Zoledronate gel","nonsurgical treatment","Intrabony Defects","type 2 diabetes","Periodontitis",{"date":324,"type":39},{"date":393,"type":22},"2026-08-07",{"date":43,"type":22},{"name":45,"class":46},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":17,"minAge":359,"maxAge":403,"enrollmentInfo":404,"targetDuration":4,"studyType":23,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100651622","effect-of-artificial-intelligence-based-cognitive-training-on-sleep-disorders-and-quality-of-life-in-patients-with-multiple-sclerosis-100651622","NCT07762326","Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis","AI","Inclusion Criteria:\n\n* Patient's age ranges from 25-40 years.\n* Patient with EDSS not more than 5.\n* Patients who have no relapses for the previous three months.\n* Patients with sufficient cognitive abilities that enables them to understand and follow\n* instructions with a score more than 24 according to the Mini-Mental State Examination scale\n\nExclusion Criteria:\n\n* Mechanical or neuromascular problems.\n* Cardiovascular problems (unstable angina, recent myocardial infarction within the last three months, congestive heart failure, significant heart valve dysfunction, or unstable hypertension) or pulmonary disorders.\n* Auditory problems.\n* Sensory impairment caused by other diseases except the MS such as diabetes mellitus.","40 Years",{"count":146,"type":22},[25],"this study will be conducted to investigate the effect of artificial intelligence (AI) based cognitive training on sleep disorders and quality of life in patients with multiple sclerosis.",[408],"Multiple Sclerosis",[410,411,412,408],"Artificial Intelligence Based Cognitive Training","Sleep Disorders","Quality of Life","2026-08-08",{"date":255,"type":39},{"date":36,"type":22},{"date":417,"type":22},"2027-03-30",{"name":45,"class":46},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":98,"minAge":360,"maxAge":225,"enrollmentInfo":426,"targetDuration":4,"studyType":23,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":442,"locationsCount":4},"100650930","aquatic-versus-land-based-exercise-in-women-with-lipedema-100650930","NCT07756463","Aquatic Versus Land-Based Exercise in Women With Lipedema","Effects of Aquatic and Land-Based Exercise on Functional, Clinical, and Lymphatic Outcomes in Women With Lipedema: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women diagnosed with lipedema for at least five years\n* Had stage 2 or 3 and type 2 or 3 disease\n* Had a body mass index of ≥25 and \\\u003C40 kg\u002Fm²\n* Able to walk independently, with or without their usual assistive device\n* Had received medical clearance to participate in moderate-intensity aquatic and land-based exercise\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Had clinically significant lymphedema, uncontrolled chronic venous insufficiency, acute thrombosis, or another major cause of lower-limb edema\n* Had open wounds, active skin infection, fever, or another infectious condition incompatible with pool use\n* Had uncontrolled cardiovascular, metabolic, respiratory, or neurological disorder that could compromise exercise safety; a cardiac pacemaker or congestive heart failure; pregnancy; active cancer or ongoing chemotherapy, immunotherapy, or radiotherapy\n* Had history of bariatric surgery, recent major surgery, or liposuction; current use of weight-loss medication\n* Had current participation in structured aquatic or lower-limb exercise exceeding the protocol-defined threshold; or severe fear of water or inability to enter and exit the pool safely.",{"count":79,"type":22},[25],"To evaluate optimal workout environments, a 12-week study assigned women with moderate-to-severe lipedema to three distinct protocols: supervised pool workouts, equivalent land-based training, or basic standard monitoring. Researchers tracked walking endurance alongside tissue composition, fluid levels, pain intensity, and general well-being. The trial posited that structured activity beats routine care alone, with water-based exercise potentially offering superior relief due to buoyancy and hydrostatic fluid compression.",[430],"Lipedema",[432,433,434,435,436,437],"lipedema","hydrotherapy","therapeutic exercise","six-minute walk test","symptom burden","quality of life",{"date":324,"type":39},{"date":440,"type":22},"2026-08-27",{"date":113,"type":22},{"name":45,"class":46},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":98,"minAge":55,"maxAge":359,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100651413","calisthenics-versus-cycling-exercises-on-interleukin-6-and-quality-of-life-in-benha-university-students-with-irritable-bowel-syndrome-100651413","NCT07760298","Calisthenics Versus Cycling Exercises on Interleukin-6 and Quality of Life in Benha University Students With Irritable Bowel Syndrome","IBS","Inclusion Criteria:\n\n* females will be aged from 18 to 25 years old\n* diagnosis by Rome IV diagnostic criteria\n* BMI will be 18.5- 29.5 kg\\\\m2\n* (Moderate-severe) severity of IBS.\n\nExclusion Criteria:\n\n* organic gastro -intestinal disorders\n* thyroid dysfunctions\n* concurrent cardio vascular?\n* respiratory, renal, hepatic disorders\n* neurological\u002Fmusculoskeletal problems,\n* psychiatric disease,\n* hematological disease,\n* previous history of stomach or intestinal excision.\n* BMI will be \\>30 kg\\\\m2\n* Participating in any other ex progrm",{"count":79,"type":22},[25],"this study will be conducted to compare between the effect of calisthenics versus cycling exercises on interleukin-6 and quality of life in Benha University students with irritable bowel syndrome.",[454],"Irritable Bowel Syndrome",[456,457,458,412,459],"Calisthenics","Cycling Exercises","Interleukin-6","Benha University Students With Irritable Bowel Syndrome",{"date":346,"type":39},{"date":36,"type":22},{"date":463,"type":22},"2027-04-20",{"name":45,"class":46},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":98,"minAge":55,"maxAge":225,"enrollmentInfo":472,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":482,"locationsCount":47},"100645934","core-based-movement-and-nutritional-counselling-for-stress-and-metabolic-outcomes-in-overweight-women-with-functional-constipation-100645934","NCT07694830","Core-Based Movement and Nutritional Counselling for Stress and Metabolic Outcomes in Overweight Women With Functional Constipation","Effects of Core-Based Movement and Nutritional Counselling on Stress, Cortisol, and Lipid Profiles in Overweight Women With Functional Constipation","Inclusion Criteria:\n\n* Female participants diagnosed with functional constipation according to Rome IV diagnostic criteria.\n* Age between 18 and 45 years.\n* Body mass index between 25 and 29.9 kg\u002Fm².\n* Ability to participate safely in the core-based movement exercise program.\n* Willingness to follow the nutritional counselling program and study procedures.\n\nExclusion Criteria:\n\n* Participants will be excluded if they have any organic gastrointestinal disorder or any disease that may affect gastrointestinal transit or colonic function.\n* Participants with inflammatory bowel disease, concurrent infectious enteritis, malignant tumors, or a history of gastrointestinal surgery, including resection of the stomach, small intestine, or large intestine, will be excluded.\n* Participants receiving steroids, antibiotics, immunosuppressive medications, or routinely using laxatives will be excluded.\n* Participants with hyperthyroidism, hypothyroidism, or other endocrine or metabolic disorders that may affect gastrointestinal function will be excluded.\n* Participants with serious cardiovascular, respiratory, renal, hepatic, hematological, neurological, or psychiatric disorders will be excluded.\n* Participants with a history or current evidence of alcohol abuse within the previous year will be excluded.\n* Participants currently engaged in an intense workout regimen will be excluded.\n* Participants with a musculoskeletal disability that may interfere with exercise applicability, such as cervical or lumbar radiculopathy, will be excluded.",{"count":79,"type":22},[25],"This study will investigate the effect of core-based movement and nutritional counselling on stress, serum cortisol, and lipid profile in overweight women with functional constipation.\n\nSixty overweight women with functional constipation will be randomly assigned into two equal groups. The study group will include 30 participants who will receive a core-based movement exercise program for 8 weeks, two sessions per week, in addition to guideline-based nutritional counselling. The control group will include 30 participants who will receive guideline-based nutritional counselling only for 8 weeks.\n\nThe outcomes will include perceived stress, serum cortisol level, lipid profile, stool form, sleep quality, and quality of life.",[476],"Functional Constipation","2026-08-06",{"date":344,"type":39},{"date":480,"type":22},"2026-08-25",{"date":417,"type":22},{"name":45,"class":46},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":225,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":498,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":509,"completionDateStruct":510,"leadSponsor":511,"locationsCount":47},"100650513","efficacy-of-artificial-intelligence-driven-program-versus-traditional-physical-therapy-program-in-patients-with-low-back-dysfunction-100650513","NCT07749833","EFFICACY OF ARTIFICIAL INTELLIGENCE DRIVEN PROGRAM VERSUS TRADITIONAL PHYSICAL THERAPY PROGRAM IN PATIENTS WITH LOW BACK DYSFUNCTION","Efficacy of an Artificial Intelligence-Driven Program Versus a Traditional Physical Therapy Program in Patients With Low Back Dysfunction","AI-LBD","Inclusion Criteria:\n\n* Adults aged 18-45 years.\n* Male or female participants.\n* Clinical diagnosis of low back dysfunction by a physiotherapist or physician.\n* Symptoms lasting more than 3 months.\n* Ability to participate in physical therapy or use AI-based rehabilitation tools.\n* Willingness to comply with the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n* Recent spinal injury or spinal surgery.\n* Previous spinal surgery within the last 6 months.\n* Severe neurological disorders (e.g., multiple sclerosis or Parkinson's disease).\n* Chronic conditions that significantly limit mobility (e.g., advanced arthritis).\n* Current use of strong opioid analgesics.\n* Severe psychiatric disorders.\n* Inability to use or access the required technology for the AI intervention.",{"count":492,"type":22},68,[25],"Low back dysfunction is one of the most common musculoskeletal disorders and is associated with pain, disability, and reduced quality of life. Artificial intelligence (AI) has emerged as a promising tool to support personalized rehabilitation by improving exercise prescription, monitoring adherence, and providing real-time feedback. This randomized controlled trial aims to compare the effectiveness of an AI-driven rehabilitation program with a traditional physical therapy program in patients with low back dysfunction. Primary outcomes include pain intensity, functional disability, and quality of life. The findings may provide evidence regarding the role of AI-assisted rehabilitation in improving clinical outcomes.",[496,497],"Low Back Pain","Low Back Dysfunction",[499,497,496,500,501,502,503,504,505,506],"Artificial Intelligence","Physical Therapy","Rehabilitation","Exercise Therapy","AI-Driven Rehabilitation","Musculoskeletal Rehabilitation","Randomized Controlled Trial","Personalized Rehabilitation","2026-08-05",{"date":393,"type":39},{"date":297,"type":22},{"date":216,"type":22},{"name":45,"class":46},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":308,"sex":17,"minAge":55,"maxAge":359,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":530,"locationsCount":47},"100645593","diaphragmatic-and-box-breathing-on-heart-rate-variability-and-perceived-stress-100645593","NCT07698652","Diaphragmatic and Box Breathing on Heart Rate Variability and Perceived Stress","Enhancing Physiological and Psychological Resilience: A Comparative Study of Diaphragmatic and Box Breathing in Physical Therapy Students.","HRV DB BB PSS","Inclusion Criteria:\n\n* Academic Status: Currently enrolled, full-time undergraduate Physical Therapy students\n* Age Range: 18-25 years\n* Health Status: Generally healthy individuals with no known chronic respiratory or cardiovascular diseases.\n* Informed Consent: Ability and willingness to provide written informed consent and commit to the 4-week protocol (6 sessions\u002Fweek).\n* Stress Level: A baseline score on the Perceived Stress Scale (PSS) indicating at least moderate stress.\n\nExclusion Criteria:\n\n* Pre-existing Breathing Expertise: Individuals with professional training in yoga (Pranayama), formal meditation, or advanced breath work that might bias the baseline results.\n* Medical Conditions: Diagnosed respiratory conditions (e.g., Asthma, COPD).\n* Cardiovascular issues (e.g., Arrhythmias, Hypertension).\n* Clinical psychological disorders (e.g., Generalized Anxiety Disorder or Panic Disorder) that may require medication.\n* Pharmacological Factors: Use of medications that influence the Autonomic Nervous System (e.g., Beta-blockers, antidepressants, or heavy use of stimulants\u002Fsedatives).\n* Substance Use: Smokers\u002FVapers\n* Excessive Caffeine \"Participants consuming more than 400 mg of caffeine per day (equivalent to approximately 4 standard cups of brewed coffee) will be excluded.\n* Recent Acute Illness: Any respiratory tract infection or fever within two weeks prior to the start of the study",{"count":79,"type":22},[25],"The goal of this clinical trial is to learn if diaphragmatic breathing and box breathing work to enhance resilience and manage stress in physical therapy students. It will also learn about their effects on overall physiological and psychological parameters. The main questions it aims to answer are:\n\nDo these breathing techniques improve heart rate variability (HRV)?\n\nHow do these interventions affect participants' perceived stress levels, cognitive performance, and academic achievement?\n\nResearchers will compare diaphragmatic breathing and box breathing to a control group to see if these non-invasive methods work to improve physiological adaptation and manage stress.\n\nParticipants will:\n\nBe randomly assigned to practice diaphragmatic breathing, practice box breathing, or join a control group Have their heart rate variability (HRV) measured as a primary sign of physiological adaptation Complete assessments to evaluate their perceived stress, cognitive performance, and academic achievement",[524,525,526],"Stress","Psychological Resilience","Healthy Students",{"date":477,"type":39},{"date":327,"type":22},{"date":43,"type":22},{"name":45,"class":46},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":543,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":551,"locationsCount":47},"100604289","effect-of-transcranial-alternating-current-stimulation-on-sleep-disorder-and-anxiety-in-elderly-population-100604289","NCT07147582","Effect of Transcranial Alternating Current Stimulation on Sleep Disorder and Anxiety in Elderly Population","Inclusion Criteria:\n\n-healthy elderly adult aged more than 60 years old, both sex, and suffering from insomnia and sleep disorders\n\nExclusion Criteria:\n\n* neurological and vascular diseases.",{"count":79,"type":22},[25],"Sleep disorders and anxiety are complicated disorders affecting population especially elderly population, therefore treating these disorders will have positive impact on population production and quality of life.",[541,542],"Chronic Sleep Disorders","Anxiety Disorder",[544,545,546],"Anxiety","Elderly","Sleep Dsorders",{"date":393,"type":39},{"date":111,"type":22},{"date":550,"type":22},"2026-11",{"name":45,"class":46},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":98,"minAge":55,"maxAge":225,"enrollmentInfo":558,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":569,"locationsCount":4},"100650892","the-value-of-pretreatment-with-letrozole-on-induction-time-of-medical-evacuation-with-misoprostol-in-cases-of-missed-abortion-100650892","NCT07753655","The Value of Pretreatment With Letrozole on Induction Time of Medical Evacuation With Misoprostol in Cases of Missed Abortion","Inclusion Criteria:\n\n* Women aged 18 - 45 years.\n* Diagnosed with missed abortion confirmed by ultrasound (absent fetal heartbeat and\u002For no embryonic development).\n* Gestational age ≤ 12 weeks based on last menstrual period\n* Hemoglobin levels \\>10 g\u002FdL.\n* BMI ranging from 25 to 35 kg\u002Fm2.\n* Hemodynamically stable and no signs of infection.\n\nExclusion Criteria:\n\n* Incomplete abortion, inevitable abortion, or threatened miscarriage.\n* Suspected ectopic pregnancy and molar pregnancy.\n* History of allergy or contraindication to misoprostol or letrozole.\n* Coagulopathy or use of anticoagulant medications.\n* Chronic medical diseases (e.g., uncontrolled diabetes, cardiovascular disease, liver or renal dysfunction).\n* Prior uterine surgery that contraindicates medical abortion (e.g., classical cesarean section, myomectomy with uterine entry).\n* Uterine anomalies.\n* Women unsure of LMP",{"count":559,"type":22},74,[25],"The aim is to evaluate the effect of letrozole pretreatment on the induction time during medical evacuation using misoprostol in women diagnosed with missed abortion, and to compare its efficacy and safety to misoprostol alone.",[563],"Letrozole","2026-08-04",{"date":393,"type":39},{"date":567,"type":22},"2026-08-15",{"date":43,"type":22},{"name":45,"class":46},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":591,"leadSponsor":593,"locationsCount":47},"100648550","intermittent-ephedrine-boluses-for-prophylaxis-against-postinduction-hypotension-100648550","NCT07722013","Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension","Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension in High-risk Patients Undergoing Major Abdominal Surgery: a Randomized Double-blinded Controlled Trial: a Randomized Double-blinded Controlled Trial","Inclusion Criteria:\n\n* Adult patients aged \\>50 years,\n* weight \\>50 kg,\n* American Society of Anesthesiologists (ASA) Physical Status score of \\> I,\n* undergoing major abdominal surgery\n\nExclusion Criteria:\n\n* Severe cardiac morbidities (impaired contractility with ejection fraction \\\u003C 40%, heart block, significant uncontrolled arrhythmias, tight stenotic valvular lesions)\n* Acute cardiovascular pathologies: acute\u002Fdecompensated heart failure, acute coronary syndrome\n* Uncontrolled hypertension (systolic blood pressure\\>150 mmHg)\n* Preoperative HR more than 110 bpm despite proper fluid management and patients with renal impairment\n* Renal impairment\n* Patients on vasopressor infusion,\n* Allergy of any of the study drugs",{"count":578,"type":22},124,[25],"The aim of this work is to assess the efficacy of intermittent ephedrine boluses in prophylaxis against postinduction hypotension in high-risk patients undergoing major abdominal surgery, compared to standard care.",[582],"Postinduction Hypotension",[584,585,586,587,588],"major abdominal surgery","high risk patients","ephedrine","prophylaxis","postinduction hypotension",{"date":477,"type":39},{"date":564,"type":39},{"date":592,"type":22},"2026-12",{"name":45,"class":46},""]